Indications of starting Statins.
Reading File
Finding Sources
Finding Sources
Searching PubMed
statins AND primary prevention
Searching the Web
ACC AHA guideline statin indications primary secondary prevention LDL 190 diabetes 2026
Quick answer
Indications for starting a statin
Statins are started primarily to reduce atherosclerotic cardiovascular disease (ASCVD) risk, including myocardial infarction and ischemic stroke.
1. Secondary prevention: established ASCVD
Use a high-intensity statin unless contraindicated or not tolerated in patients with:
- Previous myocardial infarction or acute coronary syndrome
- Stable or unstable angina due to coronary artery disease
- Prior coronary or other arterial revascularization, such as PCI/stent or CABG
- Ischemic stroke or transient ischemic attack of atherosclerotic origin
- Peripheral arterial disease, including symptomatic PAD or aortic aneurysm of atherosclerotic origin
2. Severe primary hypercholesterolemia
- LDL-C ≥190 mg/dL (≥4.9 mmol/L): start a high-intensity statin, without needing to calculate 10-year ASCVD risk.
- Consider familial hypercholesterolemia, especially with markedly high LDL-C or a family history of premature ASCVD.
3. Diabetes mellitus, age 40-75 years
- Diabetes + LDL-C 70-189 mg/dL: at least a moderate-intensity statin, regardless of calculated 10-year risk.
- Use high-intensity statin when diabetes is accompanied by multiple ASCVD risk factors, long duration, chronic kidney disease, smoking, hypertension, or age 50-75 years.
4. Primary prevention in adults without diabetes, age 40-75 years
With LDL-C 70-189 mg/dL, calculate 10-year ASCVD risk:
| 10-year ASCVD risk | Usual approach |
|---|---|
| <5% | Lifestyle treatment; statin usually not indicated |
| 5% to <7.5% | Consider moderate-intensity statin if risk-enhancing factors are present |
| 7.5% to <20% | Moderate-intensity statin is generally recommended after clinician-patient discussion |
| ≥20% | High-intensity statin, aiming for at least 50% LDL-C reduction |
5. Risk-enhancing factors favoring statin use
These can support starting a statin in borderline or intermediate-risk patients:
- Family history of premature ASCVD: male first-degree relative <55 years or female <65 years
- Persistent LDL-C ≥160 mg/dL
- Chronic kidney disease
- Metabolic syndrome
- Chronic inflammatory conditions, such as rheumatoid arthritis, psoriasis, HIV, or lupus
- History of premature menopause or pre-eclampsia
- South Asian ancestry
- Persistently raised triglycerides ≥175 mg/dL
- Elevated lipoprotein(a), apolipoprotein B, or high-sensitivity CRP
- Ankle-brachial index <0.9
6. Coronary artery calcium score to resolve uncertainty
For patients in whom primary-prevention statin treatment is uncertain:
- CAC = 0: it may be reasonable to defer statin, except in smokers, people with diabetes, or those with a strong family history of premature ASCVD.
- CAC 1-99: favors statin, especially age ≥55.
- CAC ≥100 Agatston units or ≥75th percentile: statin indicated.
Special points
- In adults older than 75 years without ASCVD, initiation is individualized based on life expectancy, comorbidity, frailty, drug interactions, and patient preference.
- Statins are generally avoided during pregnancy and breastfeeding.
- Baseline lipid profile and liver enzymes are typically checked before initiation. Assess for interacting drugs and prior muscle symptoms.
Textbook support: Goodman & Gilman’s The Pharmacological Basis of Therapeutics, primary prevention guidance: LDL-C ≥190 mg/dL warrants high-intensity treatment; diabetes age 40-75 warrants at least moderate-intensity treatment. The Washington Manual of Medical Therapeutics, secondary prevention supports high-intensity statin therapy.
Reading File
Reading File
Reading Web Page
https://www.acc.org/Latest-in-Cardiology/Articles/2026/09/01…
Indications to start a statin
Statins are used mainly to prevent atherosclerotic cardiovascular disease (ASCVD), not simply to treat an isolated cholesterol number.
1. Secondary prevention: clinical ASCVD
Start a high-intensity statin unless contraindicated or not tolerated in anyone with established ASCVD, including:
- Acute coronary syndrome or myocardial infarction
- Stable or unstable angina
- Coronary, carotid, or peripheral arterial revascularization
- Ischemic stroke or transient ischemic attack
- Peripheral arterial disease of atherosclerotic origin
Aim for at least a 50% LDL-C reduction. Clinical ASCVD is a clear indication for high-intensity therapy. The Washington Manual of Medical Therapeutics, p. 99.
2. Severe primary hypercholesterolemia
- LDL-C ≥190 mg/dL (≥4.9 mmol/L): initiate high-intensity or maximally tolerated statin without waiting for a calculated risk score.
- Consider familial hypercholesterolemia, particularly if LDL-C is very high or there is premature ASCVD in the family.
3. Diabetes mellitus
For adults 40-75 years with diabetes, begin at least a moderate-intensity statin, irrespective of baseline LDL-C or calculated risk.
Use high-intensity treatment when cardiovascular risk is higher, for example with multiple risk factors, target-organ damage, long duration of diabetes, or older age.
4. Chronic kidney disease or HIV
Under the current 2026 ACC/AHA multisociety guidance, adults aged 40-75 years with any of the following should receive LDL-lowering treatment for primary prevention without further risk calculation:
- Diabetes
- CKD stage 3 or 4
- HIV
A statin is generally the first-line LDL-lowering drug unless contraindicated or intolerable. The 2026 guideline summary specifies these groups.
5. Primary prevention based on estimated ASCVD risk
For people without ASCVD, diabetes, CKD stage 3-4, HIV, or LDL-C ≥190 mg/dL, estimate risk, currently using the PREVENT-ASCVD equation in adults 30-79 years with LDL-C 70-189 mg/dL.
| 10-year ASCVD risk | General approach to statin initiation |
|---|---|
| Low: <3% | Lifestyle first. Consider drug therapy if LDL-C remains ≥116 mg/dL despite lifestyle measures, particularly with additional risk factors. |
| Borderline: 3% to <5% | Consider a moderate-intensity statin if risk-enhancing factors are present. |
| Intermediate: 5% to <10% | Start at least moderate-intensity statin after clinician-patient discussion. |
| High: ≥10% | High-intensity statin is generally appropriate, aiming for ≥50% LDL-C lowering and LDL-C <70 mg/dL. |
| Very high risk | Treat more intensively; pharmacologic LDL-lowering is considered even with LDL-C 55-69 mg/dL. |
The risk categories and LDL-C thresholds are summarized in the 2026 ACC/AHA dyslipidemia guidance.
Risk-enhancing factors that favor treatment
These can justify a statin when the decision is uncertain, particularly at borderline or intermediate estimated risk:
- Family history of premature ASCVD
- Persistently elevated LDL-C, especially ≥160 mg/dL
- Metabolic syndrome
- Chronic inflammatory disease, such as rheumatoid arthritis, psoriasis, or HIV
- Chronic kidney disease
- South Asian ancestry
- Persistently raised triglycerides
- Elevated lipoprotein(a) or apoB
- Premature menopause, preeclampsia, gestational diabetes, or polycystic ovary syndrome
- Evidence of subclinical atherosclerosis, such as coronary artery calcium on CT
Important practical points
- Discuss expected benefit, adverse effects, drug interactions, lifestyle measures, and patient preference before treatment. The Washington Manual of Medical Therapeutics, p. 99.
- In adults over 75 years without ASCVD, initiation is individualized according to life expectancy, comorbidity, frailty, interactions, and patient preference.
- Do not start statins in pregnancy. Stop statin treatment during pregnancy and breastfeeding in most patients, except in exceptional specialist-managed circumstances.
- Obtain a baseline lipid profile and assess for secondary causes of dyslipidemia. Check ALT before treatment; check CK only if there is a myopathy history or symptoms.
This is a shared conversation. Sign in to Orris to start your own chat.